论文部分内容阅读
目的 为进一步研究国产降纤酶对脑梗死的疗效。方法 采取随机双盲对照临床研究。在应用降纤酶治疗前及用药后第 14d分别进行神经功能缺损评分 (NDF) ,并进行日常生活能力评估 (Barthel指数 )。同时检测血浆中纤维蛋白原含量、肝功和肾功。结果 降纤酶治疗组血浆纤维蛋白原含量在用药后极显著降低 (P <0 0 1)对肝功、肾功、凝血功能无影响 ,也未发生过敏反应。近期疗效降纤酶治疗组显著优于对照组。神经功能缺损评分及Barthel指数有显著进步 (P <0 0 5 )。结论 国产降纤酶为安全有效地降低血浆纤维蛋白原含量及治疗急性脑梗死有较好疗效的药物
Objective To further study the domestic defibrase on the efficacy of cerebral infarction. Methods Randomized double-blind controlled clinical study. Neurodeficiency score (NDF) and daily living ability assessment (Barthel index) were performed before defibrase treatment and 14 days after treatment. Plasma fibrinogen levels, liver function, and renal function were measured at the same time. Results The content of fibrinogen in the defibrase-treated group was significantly lower (P <0.01) than that in the untreated group, and had no effect on liver function, renal function and coagulation function, and no allergic reaction occurred. The recent treatment of defibrase enzyme group was significantly better than the control group. Neurological deficit score and Barthel index improved significantly (P <0.05). Conclusion domestic defibrase is safe and effective in reducing plasma fibrinogen content and the treatment of acute cerebral infarction has a good effect of the drug